Given the critical role of CD44 in cancer metastasis and therapeutic resistance, several strategies targeting CD44 have been developed for the treatment of diverse malignancies, including head and neck, breast, gynecological, and ovarian cancers [25]. This evidence concerns the gene CD44 and ovarian carcinoma.